SA
GILD icon

Shilanski & Associates’s Gilead Sciences GILD Stock Holding History

Shilanski & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,034
Closed -$1M – 107
2023
Q2 		$1M Buy
13,034
+360
+3% +$28.7K 0.41% 60
2023
Q1 		$1.06M Buy
+12,674
New +$1.05M 0.48% 57

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Shilanski & Associates's GILD Position: Q3 2023 in Review

Shilanski & Associates sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 13,034 shares — an estimated $1M sold.

Shilanski & Associates first reported a position in GILD in Q1 2023 and held it in 2 quarters. The position peaked at $1.06M in Q1 2023. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

  • Shilanski & Associates reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
  • Shilanski & Associates sold 13,034 Gilead Sciences shares in Q3 2023, an estimated $1M.
  • Shilanski & Associates first reported a position in Gilead Sciences in Q1 2023 and held it in 2 quarters.
  • Shilanski & Associates's Gilead Sciences position peaked at $1.06M in Q1 2023.
  • 1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Shilanski & Associates's 13F filing for Q3 2023, filed 14 Nov 2023.